• Targeting Glutaminase in Neuroblastoma: Mechanistic and Stra

  2026-07-08

  This thought-leadership article explores the intersection of epitranscriptomic regulation, spliceosomal vulnerability, and glutamine metabolism in MYCN-amplified neuroblastoma. It evaluates the mechanistic rationale and translational strategy for deploying CB-839 (Telaglenastat)—a potent, selective glutaminase 1 inhibitor—in preclinical and experimental cancer metabolism research. Integrating pivotal findings from recent PRMT5 inhibition studies, the article provides actionable guidance for translational researchers, positioning CB-839 as a bridge between advanced mechanistic insight and next-generation therapeutic development.

• Moxifloxacin Workflows: Applied Research with Fluoroquinolon

  2026-07-08

  Unlock the full experimental potential of Moxifloxacin, a benchmark fluoroquinolone antibiotic, for probing DNA gyrase inhibition, antiproliferative effects on retinal ganglion cells, and metabolic immune responses. This guide bridges mechanistic insights with practical, protocol-driven lab applications, offering troubleshooting tips and comparative workflow enhancements for reproducible, high-impact biomedical research.

• GI 254023X: Selective ADAM10 Inhibitor for Vascular and Cell

  2026-07-07

  GI 254023X empowers researchers with nanomolar, highly selective ADAM10 inhibition to dissect apoptosis, endothelial integrity, and Notch1 signaling in advanced disease models. Its robust selectivity and workflow versatility enable precise modulation of cell adhesion and barrier protection—advancing studies from cancer biology to infectious disease with unmatched control.

• A 83-01 (ALK-5 Inhibitor): Empowering Organoid and EMT Resea

  2026-07-07

  A 83-01 (ALK inhibitor) unlocks reproducible TGF-β pathway modulation, enabling precise control of organoid differentiation and EMT modeling. Here, we translate state-of-the-art workflows and troubleshooting strategies into actionable guidance for researchers seeking robust, selective inhibition in disease modeling applications.

• Exendin-4 (Exenatide): Applied Workflows for Beta Cell Resea

  2026-07-06

  Exendin-4 (Exenatide) is transforming type 2 diabetes research through potent, reproducible modeling of insulin sensitivity and beta cell function. This article unpacks rigorous workflow enhancements, troubleshooting insights, and scalable innovations rooted in recent breakthroughs—empowering researchers to optimize both cost and data quality.

• Repurposing Lopinavir for MERS-CoV: Insights from FDA Compou

  2026-07-06

  de Wilde et al. systematically screened 348 FDA-approved drugs and identified Lopinavir among four small molecules that inhibited MERS-CoV replication in cell culture. This work highlights the translational potential of rapid drug repurposing for emerging coronaviruses and provides a foundation for antiviral research using established protease inhibitors.

• Tivozanib (AV-951) in Oncology Research: Protocols & Innovat

  2026-07-05

  Tivozanib (AV-951) sets a new benchmark for precision anti-angiogenic therapy thanks to its picomolar potency and exceptional selectivity for VEGFR. This article demystifies its application in advanced in vitro workflows, highlights actionable troubleshooting strategies, and translates novel assay insights from the latest reference study.

• Masitinib (AB1010): Technical Guide for KIT and PDGFR Inhibi

  2026-07-04

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor optimized for precise inhibition of KIT, PDGFRα, and PDGFRβ. It is best suited for DMSO-based kinase assays in cancer biology, mastocytosis, and inflammation research. The compound should not be used in protocols requiring aqueous or ethanol solubility, or broad-spectrum kinase inhibition.

• NF 449 in Platelet Research: Reproducibility and Selectivity

  2026-07-03

  This article examines how NF 449 (SKU B6716) addresses core challenges in purinergic receptor research, with a focus on platelet activation and aggregation assays. Drawing on peer-reviewed evidence and validated product data, we dissect workflow scenarios to demonstrate why NF 449 stands out for selectivity, reproducibility, and experimental clarity.

• Comprehensive Metabolic Profiling of Tiamulin in Farm Animal

  2026-07-03

  This study provides a detailed analysis of Tiamulin (Thiamutilin) metabolism across multiple farm animal species using UHPLC-Q/TOF, revealing species-specific metabolic pathways and identifying marker residues relevant for food safety. The findings have direct implications for veterinary residue monitoring and inform pharmacokinetic research.

• Docetaxel in Personalized Cancer Models: Beyond Standard Che

  2026-07-02

  Explore the role of Docetaxel in advanced cancer research, with a focus on personalized assembloid models and microenvironment-driven drug responses. This article offers unique insights for oncology researchers seeking to optimize Docetaxel applications.

• AMPK’s Dual Role in Autophagy: Insights from Energy Stress S

  2026-07-02

  This article examines recent evidence that challenges the long-accepted model of AMPK’s role in autophagy, highlighting new findings that AMPK predominantly inhibits autophagy initiation under energy stress while preserving essential autophagy machinery. These insights have significant implications for understanding cellular energy adaptation and designing metabolic signaling experiments.

• Carfilzomib (PR-171): Precision Proteasome Inhibition in ESC

  2026-07-01

  Explore how Carfilzomib (PR-171) enables targeted proteasome inhibition and multi-modal cell death in esophageal squamous cell carcinoma (ESCC) research. This article delves into mechanistic insights, protocol best practices, and translational potential beyond existing overviews.

• 3X (DYKDDDDK) Peptide: Reliable Tagging for Protein Assays

  2026-07-01

  This article spotlights the scientific advantages and practical reliability of the 3X (DYKDDDDK) Peptide (SKU A6001) for cell viability, proliferation, and cytotoxicity workflows. Scenario-driven Q&As guide researchers through evidence-based solutions, protocol optimization, and informed vendor selection—ensuring robust experimental outcomes with APExBIO’s 3X FLAG peptide.

• Translating FGF-19 Mechanisms: Strategic Guidance for Metabo

  2026-06-30

  This thought-leadership article unpacks the mechanistic and translational significance of Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized) for researchers investigating metabolic regulation and inflammation. By connecting validated experimental workflows with the latest insights into FGF-19/FGFR4 signaling—and integrating emerging findings from sepsis-associated AKI research—this guide provides actionable strategies and protocol parameters for advancing reproducible, clinically relevant discoveries. The narrative spotlights APExBIO’s FGF-19 protein as a gold standard tool, and positions this discussion as a bridge between mechanistic understanding and future therapeutic innovation.

14793 records 1/987 page Next 12345 下5页 Last page